PhoreMost Achieves Second Milestone in Target Discovery Alliance with Boehringer Ingelheim
PhoreMost Introduces GlueSEEKER Platform for Discovery of Molecular Glue Degraders
PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable’ disease targets, and ThinkCyte K.K, a biotechnology company pioneering novel cell analysis and sorting instruments, have entered a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI).
CAMBRIDGE, England and TOKYO, Dec. 13, 2022 /PRNewswire/ -- PhoreMost Ltd. and ThinkCyte K.K. today announced a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI). The partnership leverages both companies' distinctive technologies in high-throughput drug discovery, PhoreMost's next-generation phenotypic screening platform, SITESEEKER®, and ThinkCyte's AI-driven cell characterization and sorting platform, Ghost Cytometry®, with the aim of developing differentiated therapies for a range of diseases with unmet clinical need.
PhoreMost Ltd., a UK-based biopharmaceutical company, has entered into a multi-project target discovery collaboration with Roche, a leading biotechnology company. Under the terms of the agreement, PhoreMost will receive an upfront payment and is eligible for preclinical success-based milestones. Further financial terms are not disclosed.
COPENHAGEN, Denmark, Sept. 14, 2021 /PRNewswire/ -- Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target drug discovery agreement with PhoreMost. Under the terms of the agreement, Vipergen will apply its high-fidelity DEL technology platforms to identify novel small-molecule compounds that bind to selected PhoreMost protein targets. PhoreMost will select hits for development into novel therapeutics for oncology. PhoreMost will retain exclusive rights to globally commercialize any products resulting from the collaboration. Financial details of the agreement were not disclosed.